Four things you should know about gene patents
The Federal Court’s decision that gene patenting is permitted in Australia will have ramifications for all gene patents, even though the case involved only one gene associated with breast cancer.
A gene patent means only the patent-holder has the right to undertake research and development involving that gene. These patents generally last for 20 years.
Saiba mais em: http://theconversation.com/four-things-you
Getty processa Microsoft por imagens digitais
A Microsoft está sofrendo um processo judicial da Getty Images, proprietária de uma das maiores bibliotecas mundiais de imagens digitais, por conta de um novo recurso em seu programa de buscas Bing que encoraja outros sites a incorporar imagens não licenciadas que encontrem na Web.
Saiba mais em: http://www1.folha.uol.com.br/mercado/2014/
Disney Tries to Prevent Deadmau5’s Mouse Ears Trademark
The Walt Disney Co. has filed an objection to musician deadmau5’s effort to trademark his signature logo, claiming that the musician’s stylized mouse ears is too similar to its iconic brand.
Saiba mais em: http://variety.com/2014/biz/news/disney-deadmau
Fresenius Kabi withdraws petitions against Pfizer cancer patents
IPAB dismisses revocation applications by Fresenius Kabi against Pfizer’s crizotinib and axitinib
Saiba mais em: http://www.business-standard.com/article/companies
ALS Association Withdraws Ice Bucket Challenge Trademark Applications Amid Backlash
The ALS Association has withdrawn applications to trademark the terms “ice bucket challenge” and “ALS ice bucket challenge,” after steps taken to claim legal rights to the phrases were met with controversy.
Saiba mais em: http://www.huffingtonpost.com/2014/09/02/
Azerbaijan finalizes preparations for intellectual property labeling
Azerbaijan’s Copyright Agency has completed technical and organizational works on implementation of special control marks in the production of intellectual property, the agency reported.
The Center for Intellectual Property Rights under the agency will regulate issuing of control marks for the objects of copyright.
Saiba mais em: http://www.azernews.az/business/70134.html
APPLE’S PATENT CLEANUP: IEVERYTHING OR ISUE?
Apple’s been granted a further 48 patents covering everything from percussion gestures in GarageBand to a surround sound MacBook. Will we see a multitude of new iThings, or just a whole lot of iCourt proceedings?
PatentlyApple noted the awarding of the new patents, which join Apple’s already abundant crop of patents covering everything from the shapes of the iPhone/iPod Touch to the packaging Apple uses for its products.
Saiba mais em: http://www.techly.com.au/2014/09/01/apples
Foreign Patent Trolls Threaten Arkansas Economy (Warwick Sabin Commentary)
At first glance, competition from overseas may not seem like one of the biggest threats to Arkansas businesses — much less from foreign governments themselves. Besides, there are countless other considerations business owners juggle daily to run a successful company. However, a troubling new trend of patent abuse sponsored by other countries is quietly reaching deep into our state, driving up costs and stifling innovation among America’s job creators.
Saiba mais em: http://www.arkansasbusiness.com/article/100546
Using post-grant proceedings to challenge pharma patents
Thanks to the Leahy-Smith America Invents Act, there are now a variety of ways to challenge the validity of a U.S. patent, such as inter partes reviews, covered business method proceedings, postgrant reviews, derivation proceedings and ex parte re-exams. It is still early in the game for many of these proceedings, and it can be difficult for a company to establish a strategy for challenging a patent, particularly in the biological/pharmaceutical space, since far fewer PTAB postgrant proceedings to date have involved biological/pharmaceutical patents than electrical/computer patents. Still, some conventional wisdom is beginning to emerge about this array of options, including whether and how these proceedings can provide effective means for challenging patents in the biological/pharmaceutical space.
Saiba mais em: http://www.lexology.com/library/detail.aspx?g
Challenges of the new rules on competition
Denigration and diversion of clients, practices of unfair competition: At the beginning of September, the amendments to the Law on unfair competition, brought by the Government Ordinance no. 12/2014, will enter into force. These changes are intended to update a regulation which, although was adopted in 1991, has proved difficult to apply in practice.
Saiba mais em: http://www.thediplomat.ro/articol.php?id=5433